Zacks: Brokerages Expect INmune Bio, Inc. (NASDAQ:INMB) Will Announce Earnings of -$0.58 Per Share

Analysts expect INmune Bio, Inc. (NASDAQ:INMBGet Rating) to announce ($0.58) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for INmune Bio’s earnings. INmune Bio posted earnings of ($0.44) per share in the same quarter last year, which suggests a negative year over year growth rate of 31.8%. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that INmune Bio will report full year earnings of ($2.02) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($1.60) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover INmune Bio.

INmune Bio (NASDAQ:INMBGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. During the same quarter last year, the business earned ($0.32) EPS.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of INmune Bio from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research note on Friday, May 13th. B. Riley lowered shares of INmune Bio from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $14.00 to $7.00 in a research report on Tuesday. Maxim Group started coverage on shares of INmune Bio in a research report on Friday, May 6th. They set a “buy” rating and a $22.00 target price on the stock. Finally, BTIG Research lowered their target price on shares of INmune Bio from $31.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday.

Shares of INmune Bio stock opened at $5.48 on Wednesday. INmune Bio has a 52-week low of $4.63 and a 52-week high of $30.37. The company has a quick ratio of 23.89, a current ratio of 23.89 and a debt-to-equity ratio of 0.19. The company’s 50-day simple moving average is $7.76 and its 200-day simple moving average is $9.49. The firm has a market cap of $98.34 million, a price-to-earnings ratio of -2.84 and a beta of 2.44.

Several hedge funds have recently added to or reduced their stakes in INMB. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of INmune Bio in the third quarter valued at approximately $31,000. Morgan Stanley grew its position in shares of INmune Bio by 97.4% in the first quarter. Morgan Stanley now owns 3,093 shares of the company’s stock valued at $37,000 after purchasing an additional 1,526 shares during the last quarter. Bank of America Corp DE grew its position in shares of INmune Bio by 109.5% in the fourth quarter. Bank of America Corp DE now owns 3,769 shares of the company’s stock valued at $38,000 after purchasing an additional 1,970 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of INmune Bio in the fourth quarter valued at approximately $79,000. Finally, Wells Fargo & Company MN grew its position in shares of INmune Bio by 338.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,509 shares of the company’s stock valued at $118,000 after purchasing an additional 8,882 shares during the last quarter. Institutional investors and hedge funds own 13.91% of the company’s stock.

INmune Bio Company Profile (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

See Also

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.